In this study, time course microarray GeneChip data were analyzed using a novel approach to identify temporal changes in uterine gene expression following treatment of immature ovariectomized C57BL/6 mice with 0.1 mg/kg 17␣-ethynylestradiol. Functional gene annotation information from public databases facilitated the association of changes in gene expression with physiological outcomes, which allowed detailed mechanistic inferences to be drawn regarding cell cycle control and proliferation, transcription and translation, structural tissue remodeling, and immunologic responses. These systematic approaches confirm previously established responses, identify novel estrogen-regulated transcriptional effects, and disclose the coordinated activation of multiple modes of action that support the uterotrophic response elicited by estrogen. In particular, it was possible to elucidate the physiological significance of the dramatic induction of arginase, a classic estrogenic response, by elucidating its mechanistic relevance and delineating the role of arginine and ornithine utilization in the estrogen-stimulated induction of uterine wet weight.
uterus; microarray; GeneChip; temporal expression ALTHOUGH ESTROGENS ARE AMONG the most widely prescribed pharmacological agents (79) , many aspects of their action following receptor binding remain unresolved. In the classic model, the estrogen 17␤-estradiol (E2) binds to the estrogen receptor (ER), causing displacement of chaperone proteins. Dimers of the estrogen-ER complexes can then act as transcription factors by binding to specific estrogen response element (ERE) sequences in the promoters of target genes, evoking a wide range of transcriptional responses. Recent research has revealed a vast spectrum of estrogen activities, which, in addition to roles in female reproduction, include regulation of bone growth and mineral density, food intake and weight gain, vascular function, immunologic responses, various neurological roles, and even in male reproductive capacities (13, 18) . These divergent actions are mediated through two ER isoforms, each exhibiting a distinct tissue distribution, coactivator and corepressor interactions, and resulting target responses (19) . Furthermore, rapid nongenomic responses mediated by short-lived membrane ERs stimulate a variety of signal transduction pathways (43, 77) . Natural products, industrial chemicals, environmental contaminants and other pharmaceutical agents have also been identified as ligands for ERs (6, 46) , but their potential to cause beneficial or adverse health effects is poorly understood.
Despite these diverse functions, the uterus continues to be a preferred model for elucidating the effects of estrogenic compounds. Temporal changes in circulating estrogen levels are critical to the normal progression of the uterine cycle and stimulate events associated with implantation in the event of ovum fertilization including the stimulation of cell cycle progression, transcription and translation of specific proteins, cellular water intake (imbibition), vascularization, recruitment of immune cells, and cell and tissue architecture modifications. ER␣ is the predominant isoform in the uterus (74) . Studies in mice with targeted disruptions have confirmed that ER␣ is required for the early hyperemia and water imbibition responses induced by estrogen, as well as later stimulation of DNA synthesis, induction of specific estrogen-inducible transcripts, and uterine growth and morphogenesis (22) .
The profound complexity of estrogen signaling underscores the limitations of current assays aimed at the detection and characterization of exogenous estrogens. Current in vitro assays do not adequately address the consequences of ER binding and subsequent gene expression (84) . By contrast, in vivo assays are based on the ability of the estrogenic substance to induce uterine weight in an immature and/or ovariectomized animal (57) . Although this protocol has been Article published online before print. See web site for date of publication (http://physiolgenomics.physiology.org).
used for decades (42) , a lack of specificity has been observed (38) , despite the incorporation of complementary uterine endpoints (i.e., epithelial cell height and number, gland number) (57, 83) . Although in vitro tests have some clear advantages, they underrepresent the sophisticated processes intrinsic to an intact animal, and conversely in vivo studies offer enhanced ability to extrapolate responses to humans, but frequently focus only on a limited number of uterinebased endpoints.
To address these issues, recent studies have examined female reproductive tract responses to estrogen using microarrays (48, 60, 75, 76) . However, the studies vary substantially in design and conditions used, as well as in the specific transcripts under consideration. Furthermore, since the dosing protocol for measuring increased uterine weight (i.e., several consecutive daily doses) may not be optimal for capturing transcriptional responses, a time course experiment examining estrogen response is desired. In the present study, a GeneChip oligonucleotide array time course was performed using the standardized uterotrophic protocol to determine the temporal effects on gene expression responses elicited by 17␣-ethynylestradiol (EE). EE is a pharmaceutical with enhanced oral bioavailability (7) that induces an estrogenic transcriptional profile similar to that of the endogenous estrogen E2 (34) . Rigorous statistical approaches were used to identify treatmentinduced changes in gene expression responses while accounting for variability between replicates. Significant responses were clustered and then associated with functional annotations extracted from public databases to identify pathways involved in the uterotrophic response.
MATERIALS AND METHODS

Uterine Time Course of Ethynylestradiol Treatment
C57BL/6 mice, ovariectomized by the vendor on postnatal day 20 and all having body weights within 10% of the average body weight, were obtained from Charles River Laboratories (Raleigh, NC) on postnatal day 26. The mice were kept in cages containing cellulose fiber chips (Aspen Chip Laboratory Bedding, Northeastern Products, Warrensburg, NY) in a 23°C HEPA-filtered environment with 30-40% humidity and a 12:12-h light/dark cycle. Animals were allowed free access to deionized water and Harlan Teklad 22/5 Rodent Diet 8640 (Madison, WI). Mice were acclimated for 4 days prior to dosing. On the fourth day, animals were weighed, and EE (17␣-ethynylestradiol; Sigma Chemical, St. Louis, MO) was dissolved in sesame oil (Loriva, Ronkonkoma, NY) to achieve the desired concentration based on the average weight of the animals (13.6 Ϯ 1.3 g). Animal groups for each dose and time point were housed in separate cages. Beginning the following day, each mouse was dosed by gavage with either a 0.1-ml dose of 0.1 mg/kg EE or with 0.1 ml sesame oil alone. An untreated animal was killed at time 0, the time at which the other animals were dosed. Duplicate animals from both the treated and vehicle-treated groups were then killed at 2, 8, 12, and 24 h. Additional pairs of animals were treated for three consecutive days with 0.1 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 EE or vehicle and then killed 24 h following the final dose, and this is referred to as the "3 ϫ 24 h" dose time point. In total, 21 animals were used. Doses were staggered to ensure that the time of exposure was within 5% of the reported dose length. Animals were killed by cervical dislocation, and uteri were excised, separated from attached connective tissue, blotted, weighed, and stored in RNAlater storage solution (Ambion, Austin, TX) at Ϫ80°C until further use. All procedures were performed with the approval of the Michigan State University All-University Committee on Animal Use and Care.
RNA Extraction, Sample Labeling, and GeneChip Hybridization
Uteri were homogenized individually as previously described (23) , and total RNA was extracted with TRIzol (Life Technologies, Rockville, MD) according to the manufacturer's instructions, with yields of ϳ3.0 g RNA/mg uterine tissue. RNA was further purified using RNeasy spin columns (Qiagen, Valencia, CA) according to the manufacturer's instructions and eluted in 20 l water. RNA yield and purity were assessed by spectrophotometer and denaturing gel electrophoresis. Ten micrograms total RNA from each uterus was then separately reverse transcribed, made into cRNA, fragmented, and hybridized to either Test2 or Test3 GeneChip arrays (Affymetrix, Santa Clara, CA) to verify target quality, and then to Mu11KSubA GeneChip arrays, which contain 6,523 probe sets directed at murine targets, according to the manufacturer's protocols.
GeneChip Data Acquisition and Clustering
Signal values and detection confidence levels were obtained using MicroArray Suite 5.0 (MAS5; Affymetrix) using the default settings. In accordance with MAS5 absolute call default parameters, a transcript was considered to be "present" (P; expressed) within a sample if the detection P value for the corresponding probe set was below 0.04 and to be "marginal" (M) if the P value fell between 0.04 and 0.06, with all other observations considered to be "absent" (A). Hierarchical and K-means clustering were performed using GeneSpring 4.2 (Silicon Genetics, Redwood City, CA).
Obtaining Updated Gene Annotation Information for Probe Set Accession Identifiers
A gene name for each probe set was obtained by using the GenBank accession identifier (GenBank ID) associated with the Affymetrix probe set identifier (probe set ID) to query a local copy of the National Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov) mouse UniGene database information (build 118), using a Perl script that returned and saved the corresponding cluster name (UniGene name), cluster identifier (UniGene ID), and gene abbreviation. mRNA RefSeq accession IDs were also saved where available. For GenBank IDs not found within UniGene, the probe set exemplar sequence was obtained from NetAffx (http://www.affymetrix.com), a BLAST search was performed against all other mouse sequences in GenBank, and a probable gene identity was assigned in cases where the five closest sequence matches all had an expect value of e Յ 10 Ϫ20 and were representative of a single UniGene cluster. Probe sets are referred to in the following text by their official gene abbreviation as obtained from NCBI.
RefSeq IDs were then used by another Perl script to query a local copy of the NCBI LocusLink database information, returning information of interest including LocusLink ID, RefSeq category, chromosomal location, Gene Ontology IDs and descriptions, and relevant NCBI PubMed references. The Lo-cusLink ID of the NCBI-MGD human homolog was also noted from the mouse LocusLink record, which in turn provided a link to additional public functional information available in the Online Mendelian Inheritance in Man (OMIM; NCBI) and GeneCards (Weizmann Institute) databases. For probe sets with a UniGene name but lacking a RefSeq ID, a modified version of the Perl script used the gene name to query the LocusLink database information, and records were inspected manually to verify that the desired record had been returned. As well, additional sequence and annotation information about each probe set was obtained from NetAffx. All Perl scripts are available upon request, in accordance with software availability guidelines proposed by the International Society for Computational Biology (http://www.iscb.org/pr.shtml#software). All tables are available in Excel format at http://www.bch.msu. edu/ϳzacharet.
In cases in which two different probe sets interrogated the same GenBank ID (referred to here as a probe set double), Microsoft Excel was used to identify probe set doubles and to determine the concordance of absolute calls on each array between probe set doubles and to examine links between these results and the probe set suffix flags (defined in Supplemental Raw GeneChip data is available in the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo) as time course experiment GSE280 and sample files GSM3870 to GSM3890. Probe set IDs, gene names and abbreviations, K-means cluster assignments, fold change calculations, and other supplemental information is available in Supplemental Table B .
Quantitative RT-PCR
RNA was isolated from uteri obtained from two additional replicates of the time course experiment described above. Verification by SYBR Green quantitative real-time PCR (QRT-PCR) of each replicate used samples consisting of equal amounts of uterine RNA pooled from five identically treated animals, so that for each treatment condition, data were collected from two separate pools each representing five different animals. Data for each time point were therefore collected separately from each of the two pools, which represent ten animals in total, and then averaged.
For each pool, 1 g total RNA was reverse transcribed using SuperScript II (Invitrogen, Carlsbad, CA) and an anchored oligo-dT primer in a 20-l reaction as described by the manufacturer. Then, 0.6 l of cDNA was added to a 30-l PCR reaction containing 0.1 M each of forward and reverse gene-specific primer, 3 mM Mg 2ϩ , 0.33 mM dNTPs, 0.5 IU AmpliTaq Gold, and 1 ϫ SYBR Green PCR buffer (Applied Biosystems, Foster City, CA). Primers (Table 1) were selected using Primer3 (62) to obtain an amplicon of ϳ125 bp length with T m of 60°C. Amplicons were selected from within the The most current gene name (UniGene build 118), abbreviation, and mRNA RefSeq ID associated with the probe set ID are provided.
Affymetrix exemplar sequence region and were compared by BLAST to all other sequences in GenBank to ensure specificity. Default cycling parameters were employed, using an ABI7000 Prism Sequence Detection System (Applied Biosystems).
Statistical Analyses
Uterine weights were assessed via a two-way ANOVA model to test for differences across treatments and across time. If the treatment-by-time interaction (trt‫ء‬time) was found to be significant, the time effect relationship was tested at fixed levels of the treatment effect.
For the GeneChip data, an empirical Bayes model (21), modified to account for an experimental design with multiple comparative variables, was used as a screening tool to identify genes that have the highest probability of being regulated due to treatment and/or time. That is, the empirical Bayes model in Ref. 21 addressed a two-sample comparison (treatment vs. control), whereas with the current experiment it is of interest to compare treatment vs. control across multiple time points. The modified approach reduces the dimensionality of the data down to a single summary statistic per gene, comparing all responses to the average response at the 2-h time point per gene, while simultaneously accounting for multiple testing issues. The empirical Bayes model estimates the a posteriori probability of being active (called p1z) with respect to treatment and/or time for each gene. In other words, the p1z value is a single summary statistic for each probe set, in which a high p1z value is indicative of a high level of response (either induction or repression) of a probe set relative to the variability in the response. The false-positive rate for a given rejection region was estimated using a Bayesian false discovery rate (FDR) (21) , and was found to be 0.52% using p1z Ͼ 0.99 as the selected threshold.
An ANOVA model was then fit to the genes with p1z Ն 0.99, and each response was classified as being active due to either a treatment effect, a time effect, or a treatment-bytime interaction. Responses with a significant (P Ͻ 0.01) treatment-by-time interaction were considered to be of interest, as were gene responses with only a significant treatment effect. Conversely, gene responses with only a significant time effect (indicative of strong vehicle-dependent or circadian responses), or responses in which the treatment and the time effects were separately significant but their interaction was not, were rejected.
For the QRT-PCR data, ␤-actin-normalized responses were standardized to the average response at the vehicle 2-h time point for each gene to adjust for gene-specific differences in expression level. An ANOVA model was fit to the data using the logarithm-transformed standardized responses from the two independent pooled samples, and gene responses were also classified as having a treatment effect, a time effect, or a treatment-by-time interaction. In addition, the Pearson correlation between the temporal responses observed by QRT-PCR and microarray prior to time-matched normalization for each gene was calculated using Microsoft Excel. A technical paper describing the details of these statistical methods is available at http://www.bch.msu.edu/ ϳzacharet.
RESULTS
Uterine Weights
The marked induction of rodent uterine hypertrophy and hyperplasia following a 3 ϫ 24 h estrogen dose is well documented with a variety of estrogens and routes of exposure (49) . An earlier and more modest induction of uterine weight due to water imbibition has also been reported at 4-6 h after estrogen exposure but is not required for the pronounced late phase uterine weight induction (4). Blotted uterine weight was induced approximately fourfold after 3 ϫ 24 h exposure to EE, while no significant increase was observed at any other time.
GeneChip Analysis
Summary statistics. A modified empirical Bayes screening approach (21) was used to identify active responses, followed by an ANOVA to remove vehicleinduced and circadian effects. This approach reduces the data to a single summary statistic (p1z value) for each probe set that is indicative of the overall level of the response relative to its variability. The p1z value reflects the responsiveness and reproducibility of a change in gene expression over time. Responsive genes were ranked according to their p1z value and a threshold value of p1z Ͼ 0.99 was initially chosen to identify ϳ15% of the probe set results for further investigation. The FDR, or false-positive rate, which addressed multiple testing issues, indicated that 0.5% of probe sets passed the threshold, or ϳ4 of the nearly 900 responses, may falsely be classified. The ANOVA did not consider multiple testing, and therefore a stringent threshold of P Ͻ 0.01 was used.
Probe sets with an absolute call by MAS5 of either present (P) or marginal (M) were relatively uniform among the arrays (45.4 Ϯ 7.9% and 2.8 Ϯ 0.4%, respectively). In addition, 17.3% of probe sets were called P on all 21 arrays, while 28.9% were called absent (A) on every array. Hierarchical clustering in GeneSpring using default settings indicated that the untreated sample, the 24 h EE-treated samples, and the 3 ϫ 24 h EE-treated samples formed three distinct groups, whereas the 8 h and 12 h EE-treated samples together formed an additional group, and the 2 h EE-treated samples could not be distinguished from the vehicletreated samples (not shown).
A gene name and associated publicly available annotation were linked to each probe set where possible by submitting the GenBank ID for the probe set to the NCBI mouse UniGene database (build 118, December 2002; Fig. 1 ). We found that 57.2% of the probe sets had an associated gene name, whereas 36.7% were denoted as ESTs. The remaining 6.1% were no longer represented in UniGene, but for those that were retained by subsequent screening steps, a tentative gene identity was assigned based on BLAST searching of the GenBank database. In some cases several probe sets were associated with the same UniGene identifier, and as a result, 6,261 unique UniGene IDs were found to be represented on the GeneChip (i.e., 4.0% redundancy).
Assessing performance of pairs of probes interrogating the same GenBank accession. Following the GenBank ID, Affymetrix probe set IDs have an appended abbreviation (referred to here as a suffix flag, see Supplemental Table A) indicating the selection rules used in determining the probe sequences comprising the probe set (2) that may significantly affect data interpretation. Only 31.7% of the probe sets had no suffix flag ("none") indicating selection using the optimal rules. A majority (55.1%) belonged to the "s" (similar) suffix flag, in which the probe set interrogates a region shared by more than one transcript, while the remaining probe sets were mainly members of the "f " (family; 6.3%) and "g" (group; 5.8%) cases.
GeneChips often have GenBank IDs represented by multiple probe sets, with each probe set associated with a different suffix flag. On the Mu11KSubA array, 433 GenBank IDs are represented by two probe sets (referred to here as doubles), which facilitates a comparison of results obtained from members of a double. All "g" probes have a corresponding "none" probe, and this comprises the majority of the probe set doubles ("g-none" 87.8%). The remaining pairs were "f-i" (5.8%), "i-s" (2.5%), "r-s" (2.3%), "f-r" (1.4%), and "i-r" (0.2%).
Absolute "present" (P) and "marginal" (M) calls were compared across the 21 arrays to evaluate the performance of probe pair doubles. At the extremes, 29.1% of doubles had at least 20 identical calls, while 5.1% of doubles had only one or zero identical calls. Upon further examination, no association between the proportion of identical calls within the double and the specific pair of suffix flags within the double was evident (not shown). Interestingly in 22 cases, one probe set within the double was called P/M on all 21 arrays while the other probe set was called A on every array (i.e., all-P/M-all-A probe set doubles). In 16 of the 17 cases (94.1%) of a "none-g" double, the "none" array was all-A while the "g" array was all-P/M. Similarly, for the 34 doubles in which there were between 16 and 19 differences in absolute call across the arrays, there were 20 doubles (58.9%) with a highly A "none" probe and a highly P/M "g" probe, but only two doubles (5.9%) with the reverse pattern. Overall, this suggests that the "none" probe set, designed using the ideal probe set rules, is not able to detect the presence of the corresponding transcript, whereas the permissive "g" probe set interrogates a transcript which may be similar but not identical to that indicated by the probe set ID.
Cluster analysis: complete dataset. Temporal patterns of gene expression within the data were initially analyzed by K-means clustering using the correlation distance metric on the entire dataset for the five time points. The average of the duplicate responses at each time point divided by the average of the corresponding duplicate vehicle responses was examined (i.e., timematched normalization). Eight K-means clusters best described the main temporal patterns based on visual inspection (Table 2) . Cluster H, the largest cluster, contained the least responsive probe sets and had the lowest proportion of all-A probe sets (17.8%). All clusters had a majority of probe sets corresponding to named genes in UniGene (53.6-59.5%), with the exception of cluster D (46.6%), which had a majority of probe sets being represented by ESTs.
For comparison, the gene expression patterns in each cluster were also viewed in a non-time-normalized form, in which the averages of the duplicate EEtreated responses were graphed separately from the averages of the duplicate vehicle-treated responses. Overall the patterns appeared as expected, with, for example, cluster A being composed mainly of genes that were relatively unchanged over time in the vehicle-treated samples while being highly induced at 2 h in the EE-treated samples. Importantly, however, other responses were also seen, such as essentially flat responses with slight differences at one time point that were greatly amplified by the ratio calculation during the process of time-matched normalization.
Screening to identify most active gene responses. To eliminate negligible or confounding responses, an empirical Bayes model was used to generate p1z values ranging from 0 to 1 for each probe set, a summary statistic that indicated the degree of the response relative to its reproducibility as a measure of probe set variability. At a threshold of 0.99, 881 probe sets were retained, of which nearly 500 were associated with a p1z greater than 0.999, indicative of a robust response with low variability between replicates. Of the 881 Fig. 1 . Probe sets represented on the Mu11KSubA array were categorized according to the gene name available in UniGene (build 118) and results from the screening steps. Percentages are relative to the 6,523 noncontrol probe sets represented on the array. For simplicity, the 398 probe sets not represented in UniGene are grouped with those for which only an expressed sequence tag (EST) designation is available within UniGene, and these are labeled "EST/not in UniGene," with further explanation provided in the text. A heavy outline indicates those probe set responses that passed the empirical Bayes (p1z Ͼ 0.99) and ANOVA (P Ͻ 0.01) screening steps and were subsequently subjected to K-means clustering.
significant probe sets, 537 (62.2%) had a gene name in UniGene, a percentage slightly higher than the proportion of named probe sets represented on the array as a whole (57.2%), suggesting that probe sets found in the present experiment to be significantly regulated were not much more likely to be annotated than randomly selected probe sets on the array.
The second ANOVA screening step was designed to identify significant (P Ͻ 0.01) treatment effects or treatment-by-time interactions, thereby eliminating vehicle or circadian effects for which the only significant effect would be time. Of the 392 that were considered to have a significant treatment effect or treatment-by-time interaction, 247 (63.0%) had an associated UniGene gene name (Fig. 1) , again indicating that the proportion of uncharacterized ESTs among the highly responsive final probe set list was no less than the proportion in the entire probe set population on the Mu11KSubA arrays. The complete list of 392 highly responsive probe sets is available in Supplemental Table B and at http://www.bch. msu.edu/ϳzacharet.
Quantitative RT-PCR. QRT-PCR was used to verify selected response patterns in uteri collected from experiments using the same protocol. A subset of 26 probe sets was randomly selected for verification that spanned the range of p1z values. Overall, there was good agreement between the GeneChip and QRT-PCR results for responsive probe sets and lower correlation in cases where no response was evident, since values then tended to fluctuate without pattern by both methods. Furthermore, in a few cases no correlation value was calculated since no transcript was detectable by QRT-PCR. Therefore, in addition to correlation analysis, a qualitative assessment based on visual inspection was also provided (Table 3) .
Arg1, Egr1, and LOC207933 (Ippi) ( Table 3 ), all of which passed both GeneChip screening tests, were associated with significantly treatment-affected QRT-PCR results. The magnitude of induction of Arg1, a classic estrogen-induced response, was strikingly similar for the GeneChip and QRT-PCR data (228-and 233-fold at 3 ϫ 24 h, respectively). Egr1 was induced 2-to 3.5-fold at 2-12 h by both measures, while Ippi was induced up to 7-fold at 8-3 ϫ 24 h by microarray but up to 12-fold at 8-24 h as measured by QRT-PCR.
At the other extreme, Saa4, Fcgr1, and Krtap8-2 were all undetectable in every sample when measured by either technique. Nxf1 was also absent or nearly absent in all samples, consistent with the microarray data. By contrast, only QRT-PCR was able to detect Tbx6, C2ta, and Crygs with a treatment effect at or near P ϭ 0.05, whereas these responses were muted or not evident in the GeneChip data. Mapk1 was also absent or nearly absent in all samples by microarray, whereas slight induction at 12 h was measured by QRT-PCR.
Repression of Tgfb3, Lepr, Capn10, and Ltbr was more pronounced in QRT-PCR measurements, and statistical correlation between the two measures was moderate, although qualitatively there was good agreement. Pdi2 responses for the two measures were highly correlated but more pronounced in the GeneChip data. Comparable results were also observed with Sftpd, C3, Farsl, Idb3, Vegfb, and Ccnb1. Csf1, S100a6, Idh2, and Fkbp10 were detectable by both methods but not greatly affected by treatment. Overall, responses were qualitatively similar, while statistical differences appeared to be due to variation between the duplicate measurements in isolated cases or to the higher sensitivity of QRT-PCR in detecting some transcripts.
Cluster analysis: reduced dataset. K-means clustering requires that the number of clusters be specified a priori. Visual inspection of 2-15 K-means clusters indicated that the time-normalized data for the reduced list of probe sets was best described using seven clusters (Table 4 and Fig. 2 ). Viewing the corresponding non-time-normalized data revealed, as expected, that overall these probe sets were very responsive to estrogen treatment but showed little response to vehicle alone. Attempts to further stratify the data into subclusters confirmed the clustering of only a single temporal gene expression pattern. While clusters J and L both contained some responses that were induced at both 8 and 12 h, seven clusters categorized the observed temporal responses more completely than did six. Clusters corresponding to late responses (i.e., clusters M, N, and O) had the highest proportion of probe sets with UniGene annotation information (72.0-78.6%; Table 4 ). For clarity, probe sets corresponding both to unnamed UniGene clusters and those not represented within UniGene are denoted "ESTs." 1 Number of probe sets classified as "absent" ("A") on every array by MicroArray Suite 5.0 (MAS5) analysis software. 2 Number of probe sets with an associated gene name in UniGene (build 118). For each GeneChip probe set, the calculated p1z value for the microarray data is provided, as well as the significance (S; P Ͻ 0.01) or nonsignificance (NS) of the subsequent treatment (trt) effect or treatment‫ء‬time interaction (trt‫ء‬time), assessed by ANOVA for probe sets with p1z Ͼ 0.99. The number of arrays on which the probe set was considered "present" or "marginal" (No. P/M) is also provided. For the RT-PCR data, the P values for the treatment (trt) and time effects, as well as the trt‫ء‬time interaction, are provided, and the result is summarized as significant or nonsignificant (P Ͻ 0.05). The Pearson correlation coefficient (correl.) comparing the microarray and RT-PCR responses is reported. 1 Number of arrays on which the probe set response was considered either "present" or "marginal" in the GeneChip data. An intensity value is available in each case regardless of whether the response is classified as "present," "marginal," or "absent." 2 The p1z value in the empirical Bayes screening.
3 P values for the treatment (trt), time, and interaction (trt‫ء‬time) terms in the ANOVA analysis for responses with p1z Ͼ 0.99. 4 A summary of the ANOVA results of the GeneChip data as significant (S) or nonsignificant (NS), using a threshold of P Ͻ 0.01 for trt and trt‫ء‬time, as described in the MATERIALS AND METHODS. NA indicates that the analysis was not performed for responses with p1z Ͻ 0.99.
5 P values for trt, time, and trt‫ء‬time in the ANOVA analysis for all quantitative real-time RT-PCR (QRT-PCR) results. ND indicates that the transcript was not detected. 6 A summary of the ANOVA results of the QRT-PCR data as significant (S) or non-significant (NS), using a threshold of P Ͻ 0.05 for trt and trt‫ء‬time. 7 Pearson correlation coefficient comparing GeneChip and QRT-PCR temporal responses, as described in the MATERIALS AND METHODS, with 1 indicating perfect correlation. NA indicates that no comparison could be made because the transcript was not detected by QRT-PCR. 8 Qualitative assessment of agreement between GeneChip and QRT-PCR data as strong (ϩ), moderate (Ϯ), or poor (Ϫ). 
Responses Not Observed
Numerous responses were observed that agree well with published data, as described in the DISCUSSION. However, there were also several well-established estrogen-regulated responses not observed in this study, including Cdk5 (p1z ϭ 0.130) (3), Ccnd3 (p1z ϭ 0.997) (3, 25) , estrogen-responsive finger protein (Trim25; p1z ϭ 0.999) (50), Rb1 (p1z ϭ 0.559) (27) , and syndecan 3 (Sdc3; p1z ϭ 0.248) (63) . In several cases, they were associated with low p1z values or lacked a significant treatment-by-time interaction ANOVA term, and in some cases these were considered absent by the MAS5 software. The lack of concordance may also be due to differences in experimental protocols, sensitivity of the methods, and specificity of the probe sets, including the possibility that "s" and "f" probe sets interrogate transcript variants not detected in previous reports. As a result, it is expected that reporting the full probe set name, including the suffix flags (Supplemental Table  B) , will facilitate comparisons with future studies. The well-characterized estrogen-inducible transcripts lactoferrin (70) and progesterone receptor (73) were not represented on the Mu11KSubA array.
DISCUSSION
Specific Responses
Examination of changes in gene expression identified temporal effects on cell cycle, DNA replication, RNA synthesis, protein synthesis and modification, immune responses, energy utilization, and solute transport, as well as evidence for effects on a number of other responses (Fig. 3) . Concordant results are often seen with previous reports using different study designs (e.g., species, strain, age, route of exposure, dose level, type of estrogen, and platform used) (48, 60, 75, 76) . Specific discussion of other modes of regulation (e.g., translational and posttranslational) of the genes mentioned here is beyond the scope of the present work; however, this information can also be important to understanding the impact of estrogen on uterine physiology.
Results that are representative of pathways important in uterine biology are discussed in the following sections, and summarized graphically in Fig. 3 .
Cell cycle. Estrogen treatment of sexually immature or ovariectomized rodents with low circulating estrogen levels initiates synchronized uterine cell proliferation (10) . Estrogen causes quiescent (G 0 ) cells to enter the G 1 growth phase, followed by DNA synthesis (S phase), a second phase of growth (G 2 ), and finally mitosis (M), after which the daughter cells start a new G 1 phase. Although many cell cycle-related changes are nontranscriptional events, others are wholly or partially regulated at the mRNA level.
Early induced transcripts (2-12 h) serve essential roles in the G 1 /S phase transition, whereas those directly involved in DNA synthesis or in the G 2 /M or M/ G 1 transitions were upregulated at 24 h and possibly sustained to 3 ϫ 24 h (Supplemental Table C ). This is consistent with reports that only 3% of cells are in S phase at the time of dosing, whereas 75% have progressed to S phase by 15 h after E2 treatment (10) , and that the rate of DNA synthesis is maximal by 24 h (28, Table 4 ). A pseudogene line is drawn in bold yellow to illustrate a representative response that defines the response pattern in each cluster. 41 ). Few responses involved in cell cycle control or DNA synthesis were regulated as rapidly as 2 h (i.e., as were members of cluster I) or after maximal uterine proliferation was achieved at 3 ϫ 24 h (i.e., as were members of cluster O).
Gadd45a (cluster I), an early response, provides a crucial link between the p53-dependent cell cycle checkpoint and DNA repair. Its levels are highest in G 1 , with a sharp drop during S phase, and it is upregulated following estrogen treatment (48, 60, 75) . Cyclin D2 (Ccnd2; cluster J), which was also upregulated in the G 1 /S transition, is induced at mRNA and protein levels in the early proliferative stage of the human endometrium (11) . Studies have also shown that cyclin D2 is highly induced at 2-8 h after estrogen injection and returns to baseline levels by 12 h (3). As well, the cdc2 activator cyclin B1 (Ccnb1; p1z ϭ 0.964) was upregulated late, consistent with its reported upregulation during G 2 /M (85). Cdc2a (cluster N) was induced at later time points, although this has been reported not to be reflected at the protein level (82) . Moreover, cyclin G2 (Ccng2; p1z ϭ 0.999), which is upregulated in the late S phase (33), was repressed 10-fold at all treatments between 8-3 ϫ 24 h. To our knowledge, other cell cycle-related transcripts (Supplemental Table C) have not been previously reported to be affected by estrogen.
Chromosome replication is an integral part of the cell cycle, and several EE-regulated genes are involved in DNA synthesis including Nme1 (cluster L), a nucleoside diphosphate kinase important in dNTP synthesis (75) ; the two subunits of ribonucleotide reductase, Rrm1 (cluster K), which is typically undetectable in quiescent cells (51); a thioredoxin-like transcript, Txnl2 (cluster J) (45) ; and thymidine kinase Tk1 (cluster M). Tk1 upregulation is associated with proliferating cells and serves as a marker for the onset of S phase (60, 64) .
Several protooncogenes, including Fos, Jun, and Myc (78), show rapid, well-characterized estrogen inducibility in the uterus but were not represented on the array. Myb (cluster N), however, is upregulated at the G 1 /S phase transition during cell proliferation (71) and was upregulated at 3 ϫ 24 h in the present study. In addition, the Myb binding protein Mybbp1a (cluster J) was also upregulated, possibly to assist Myb, which Fig. 3 . Summary of temporal uterine responses observed in response to estrogen. Time after estrogen exposure is indicated along the top, selected physiological processes are listed on the left, and blocks represent times at which changes in gene expression important to these responses were observed. Cell cycle-related genes important in the G1/S transition are upregulated at early time points, followed by those important in S phase and then G2/M. With regards to DNA synthesis, there is an early induction of transcripts involved in NTP and dNTP synthesis, while gene responses involved in dNTP breakdown are induced when maximal uterine growth has been achieved. In the case of RNA and protein synthesis, transcripts corresponding to RNA polymerase components, poly-A binding protein, tRNA-synthetases, and eukaryotic translation initiation factors (eIFs) are induced only at 8-12 h. The response pattern of transcripts involved in the immune response is complex, as described in the text. Within the complement system, an early repression of protectin expression, which functions to inhibit complement-mediated lysis, is followed by a marked induction of complement component transcripts at 3 ϫ 24 h. A transcript involved in ATP synthesis was induced by 2 h, followed by induction of transcripts involved in ATP transport, and a transcript involved in chloride transport and water balance was induced only at 3 ϫ 24 h. may play a critical role in cell proliferation and development.
RNA and protein synthesis and modification. Uterine transcription increases 6-8 h after estrogen exposure (5) . Several transcripts with roles in RNA synthesis were significantly altered following estrogen treatment (Supplemental Table D ). Novel responses identified in cluster J (8-12 h) include: arginine methyltransferase (Hrmt1l2), which methylates H4 histones and may be essential to pre-mRNA processing (47); small nuclear ribonucleoprotein Snrnpa, which functions as a spliceosome component to excise introns from pre-mRNA; EBNA1 binding protein Ebp2, which plays a role in pre-rRNA processing, and poly(A) binding protein Pabpn1, which is required for efficient poly(A) tail formation and control of tail length; and Paf53 (p1z ϭ 0.973), an activating subunit of RNA polymerase I, which was induced as previously reported (75) . Importantly, the use of global GeneChip signal normalization suggests that in samples where overall transcript levels are increased, the intensity of the signals on these arrays may be underestimated. When numerous responses are identified that are not estrogen regulated, however, these may be used to normalize overall signal intensity levels across arrays.
EE also regulated several amino acid synthesis and transfer genes including cysteinyl-tRNA synthetase (Cars), alanyl-tRNA synthetase (Aars), and asparagine synthetase (Asns) in cluster J and asparaginyl-tRNA synthetase (Nars) in cluster L. Phenylalanine-tRNA synthetase (Farsl, p1z ϭ 0.678), seryl-tRNA synthetase 1 (Sars1; p1z ϭ 0.248), and arginyl-tRNA synthetase (Rars; p1z ϭ 0.846) transcripts displayed nearly identical patterns of induction but with greater variability. No response was observed for other tRNA synthetase probe sets [aspartyl-tRNA synthetase (Dars; p1z ϭ 0.938), seryl-tRNA synthetase 2 (Sars2; p1z ϭ 0.504), tyrosyl-tRNA synthetase (Yars; p1z ϭ 0.900), or lysyltRNA synthetase (Kars; p1z ϭ 0.131)]. EE induction of histidyl-, glutamyl-, lysyl-, phenylalanine-like-, and seryl-tRNA synthetases as well as asparagine synthetase were also previously reported (75) . In addition, the dehydrogenase Mthfd2 (cluster M), which may provide the formyltetrahydrofolate for formylmethionyltRNA synthesis, was also induced (75) . Several chaperonin transcripts [i.e., Hspa8, Hspa4, and Hspa5 (also known as BiP); clusters J and L] were also induced consistent with previous reports (17, 58) , as well as numerous translation initiation factors [i.e., Eif2a, Eif2s2, Eif4a1, Itgb4bp (also known as Eif6), Eif1a, and Eif2b1].
Protein modification or degradation genes such as peptidyl arginine deiminase Pdi2 (cluster M), which converts arginine to citrulline residues, and transglutaminase Tgm2 (cluster N), which links proteins through peptide bond formation and is also implicated in apoptotic body packaging, were upregulated. Cystatin B (Cstb; cluster J), an inhibitor of apoptosis (76) and of the cathepsin family of thiol proteases, was also induced, as was one of its target cathepsins (Ctsb; cluster L). Meanwhile Spi1-3 and Spi1-5 (cluster O), members of the serine protease inhibitor family with similarity to ␣1-antitrypsin, and proteasome subunits Psmb3, Psmd2, Psma3, Psmb6, and Psmb7 (clusters J and L) exhibited upregulation.
Matrix metalloproteinase (MMP) family members are involved in structural changes associated with the cycling human endometrium (65) . MMPs degrade extracellular matrix components such as proteoglycans, fibronectin, elastin, casein, and gelatins and are involved in the breakdown of extracellular matrix during reproduction and tissue remodeling. Mmp7 (cluster O) was induced, whereas other members of the MMP family including 2, 12, 14, 15, and 24 were unaffected by EE treatment in this study. None of the tissue inhibitor of metalloproteases (TIMP) isoforms was represented on the array.
Immune and complement activation. Early uterine responses to estrogen include characteristic inflammatory responses such as edema, enhanced vascular permeability, eosinophil infiltration, and subsequent production of inflammatory mediators (14) . Eosinophil infiltration is also stimulated at estrus, with eosinophils undergoing degranulation during ovulation and characteristically releasing eosinophil peroxidase following estrogen exposure (52) . Recruited eosinophils are not required for induction of uterine wet weight, protein synthesis, or epithelial complement C3 synthesis, but may play a role in endometrial stromal remodeling (54) .
Decreases in progesterone levels during the uterine cycle, rather than direct action of estrogen, may stimulate cytokine release, attraction of eosinophils, release of the degradative MMPs, vasoconstriction, and hypoxia. Hypoxia in turn induces mediators such as vascular endothelial growth factor (Vegf), which is angiogenic and may promote edema by enhancing vascular permeability (14) . However, the increase in uterine neutrophil and macrophage content is independent of progesterone or its receptor, confirming the critical role of estrogen (72) . Moreover, the chemokine responsible for estrogen-induced eosinophil infiltration was recently identified as eotaxin (26) .
Immunologically relevant genes induced by EE treatment (Supplemental Table E ) include chemokine orphan receptor Cmkor1 (cluster I) (75) , two members of the suppressor of cytokine signaling (SOCS) family Socs3 (cluster I) and Socs1 (cluster J), interleukins Il25 (cluster L), and Il17 (cluster M), interleukin-4 receptor Il4ra (p1z ϭ 0.999) (58), the protooncogene tyrosine kinase Lyn (cluster N), which is required in immunoglobulin-mediated signaling, the well-characterized estrogen-inducible transcript for polymeric immunoglobulin receptor (Pigr; p1z ϭ 0.952), formerly referred to as secretory component (67) , and the monocyte chemotactic protein Ccl2 (also known as MCP1 or JE) (cluster L) (12) . A probe set highly similar to macrophage migration inhibitory factor (Mif; cluster L), a lymphokine that stimulates immune cell activation and cytokine production, was also induced in the present study at 8-3 ϫ 24 h (60).
Complement component factor precursor H2-Bf (cluster N) (also known as Factor B), which stimulates the proliferation of activated B-cells and is expressed at high levels in the luteal phase of the human and rodent uterine cycle (29) , was also induced. The active H2-Bf cleavage product associates with the complement C3 degradation product C3b to form C3 convertase of the alternative complement pathway. However, complement component factor Cfi (cluster O), which inactivates complement components including C3b, was also significantly upregulated. C3 itself was upregulated at 3 ϫ 24 h also, although associated with a low p1z value (p1z ϭ 0.131) due to variability. C3 is a well-characterized ERE-regulated response that is involved in phagocytic and immunoregulatory processes (58) , but the significance of the concurrent upregulation of C3 as well as both the H2-Bf activator and Cfi inactivator is confounding. Furthermore, the antigen Cd59a, or protectin (cluster I), which inhibits the terminal step of the complement activation cascade, and the activation of complement component C1r (cluster I), which is involved in activation of the first step of the classic complement system, were significantly repressed by EE. This complex transcriptional regulation of the complement pathways is poorly understood and requires further examination at the protein level and in situ studies to identify the cell types involved.
Other responses. Several genes representing a multitude of pathways and functions consistent with uterine physiology were found to be affected by EE treatment (Supplemental Table F ). For example, upregulation of proapoptotic genes [i.e., Egr1, Klf4, Cdkn1a (also known as p21), lymphotoxin B receptor (Ltbr), Pea15, Tia1] may contribute to the attenuation of cell proliferation as maximal growth is achieved, similar to the apoptotic phase that follows endometrial proliferation in the cycling uterus (32, 66) . Secreted frizzledrelated protein Sfrp2 (cluster I), which appears to function as a Wnt receptor and may have a role in apoptosis (17) , was downregulated. The repression of other apoptotic inducers (i.e., Bcl2-like 11, caspase 2 and 6, Bok) suggests complex interactions between cell types within the proliferated uterus.
Ion transporters [i.e., cystic fibrosis transmembrane regulator Cftr (59), amiloride binding protein Abp1, or diamine oxidase (cluster O)] critical to uterine fluid balance were induced by EE. Cftr and the epithelial sodium channel (ENaC, or Scnn1; not represented on the Mu11KSubA array) isoforms regulate chloride and sodium balance, respectively (9) . Furthermore, the ion channel Fxyd5 (cluster J), was induced, and although its ion transport capacity is poorly characterized, it is the homolog of human dysadherin, which inhibits E-cadherin (Cdh1; not represented on the array) function, an important component of epithelial cell adhesion (36) . Mucin Muc1 (cluster N), an anti-adhesion molecule induced by estrogen through an ERE-independent mechanism (86) , and another inhibitor of E-cadherin, increased steadily from 8 h to 3 ϫ 24 h. Muc1 has been shown to be important in the structure and function of the uterine luminal epithelial layer (8) .
The hypoxia-inducible factor Hif1a (cluster K), which is implicated in angiogenesis, apoptosis, and energy metabolism, was upregulated in agreement with a previous report (16) , while the poorly characterized hypoxia-induced gene Hig1 (cluster K) was also induced. Regulation of Hif1a in the uterus is not well understood, but a direct role of hypoxia in inducing Hif1a in the estrogen-stimulated uterus has been questioned (16) . By contrast, the rapid induction of the EREcontaining vascular endothelial growth factor, Vegf, in the uterus is well established (16, 35) , although in the present study Vegfa was highly variable (p1z ϭ 0.052). Vegf induces vascular permeability, and its inhibition abrogates the estrogen-induced uterine edema response (61) .
Protein S␣ (Pros1; cluster I), which inhibits blood clotting, and the tissue plasminogen activator Plat (cluster J), a serine protease that activates the fibrinolytic enzyme plasmin, were both highly repressed. No change was observed in the plasminogen activator inhibitor known as Pai1 or Serpine1 (p1z ϭ 0.846), while two other probe sets with important roles in the cycling uterine endometrium, the urokinase plasminogen activator Plau and the potent vasoconstricting endothelin Edn1 (65), were not represented on the array.
The dramatic changes in the proliferating uterus have extensive energy requirements. Responses induced to meet this need included the late upregulation of the carbonic anhydrase Car2 (cluster M), which is involved in many biological processes due to its role in the reversible hydration of carbon dioxide. Creatine kinase Ckb (cluster J), which has well-characterized rapid estrogen inducibility (40) and is important in generating ATP in tissues with high and fluctuating energy demands, was also upregulated (34, 48) . In addition, probe sets for the ATP transporter Slc25a5 or ANT2 (cluster L) were found to be induced, further facilitating energy needs (1, 60) .
A Proposed Model for Arginine and Ornithine Utilization
Integration of these results with previous reports provides compelling evidence of the convergence of multiple pathways regulated by estrogens that support the uterotrophic response. Although not fully elucidated, Fig. 4 depicts estrogen regulation of arginine and ornithine utilization and a model for EE-induced promotion of uterine proliferation and its subsequent mitigation.
In this model, Myc/Max induces ornithine decarboxylase expression (Odc; p1z ϭ 0.999 and ANOVA P values near significance threshold) (53), elevating Odc transcript levels at 8-24 h, as previously characterized (15, 44) . Odc catalyzes the first and rate-limiting step in the synthesis of polyamines, proline, creatine, and GABA (37) , which are involved in mitotic spindle formation and chromatin condensation, and plays an es-sential role in cell proliferation and differentiation (68) . Meanwhile, the Myc/Max inhibitor Mxi1 (80) (p1z ϭ 0.999, and near significance in the ANOVA screening) is concurrently repressed 10-fold to nearly undetectable levels. Furthermore, the Odc antizyme (31) Oaz2 (p1z ϭ 0.937) is repressed from 2-3 ϫ 24 h, while transcript levels of the Oaz inhibitor (30) Oazi (p1z ϭ 0.242) are nearly undetectable. These conditions (i.e., repression of inhibitors of Odc expression) provide an environment in which Odc transcription is favored, and polyamine synthesis proceeds during G 1 (39) . Meanwhile, the key multifunctional substrate arginine is used in protein synthesis by arginyl-tRNA synthetase (Rars), and nitric oxide (NO), the potent and multifunctional signaling molecule formed from arginine by nitric oxide synthase 3 (Nos3), is elevated in mice after 24 h estrogen exposure (81) . Although not represented on the microarray, Nos3 was found by QRT-PCR to be induced twofold at 2-8 h (data not shown). Inhibitors of nitric oxide synthase block estrogen-induced uterine edema and growth that can be overcome by pretreatment with exogenous arginine (56) . Consequently, these activated pathways converge to promote uterine growth and remodeling.
As maximal uterine growth is achieved, marked induction of the polyamine acetyltransferase Sat (p1z ϭ 0.952) and the arginase Arg1 (cluster O) at 3 ϫ 24 h reduce ornithine and arginine availability to slow proliferation. Sat is the rate-limiting enzyme in the polyamine degradation pathway, and its involvement in uterotrophy has been demonstrated by the uterine hypoplasia in mice overexpressing Sat (55) . Induction of uterine arginase activity is well established as a classic biomarker for estrogen action (24) ; however, it has also been reported to be induced by Tgfb1 (not represented on the array), which itself is known to be rapidly induced by estrogen (69) . Although the biological significance of Arg1 mRNA (230-fold at 3 ϫ 24 h) and enzyme induction has not been previously characterized, results from this study indicate an important role in the depletion of ornithine as maximum induction of uterine weight is realized. In addition, Arg1 induction, mediated by decreased ornithine levels or by the transcriptional Fig. 4 . Proposed model for estrogen-induced promotion of uterine growth through regulation of specific urea cycle product levels. The Myc/ Max protein complex induces ornithine decarboxylase (Odc) transcription at 8-24 h, while the Myc/Max inhibitor Mxi1 and the Odc antizyme Oaz2 are concurrently repressed, and the Oaz inhibitor Oazi remains undetectable. Odc transcription is favored, and polyamines essential for growth are synthesized in G1. Arginine, meanwhile, is used for protein synthesis by arginyl-tRNA synthetase (Rars) and for the production of the multifunctional signal nitric oxide by the inducible synthase Nos3 (measured by QRT-PCR in the present study). At 3 ϫ 24 h, uterine growth is maximal, increasing nitric oxide levels inhibit Odc, and depletion of ornithine relieves inhibition of Arg1. Polyamines and arginine are metabolized by Sat and Arg1, respectively, which are highly induced at 3 ϫ 24 h, to relieve growth stimulation. The peptidyl arginine deiminase Pdi2 was also highly induced at 3 ϫ 24 h and may also act to decrease arginine levels, although its action on free, nonpeptide substrate is not well defined. Further explanation is provided in the accompanying text. Red indicates upregulation, blue indicates downregulation, green indicates that the transcript was considered nondetectable (N.D.) under all conditions, and gray indicates that the transcript was not represented on the array. activator c/EBP␤ or the growth factor Tgfb1 (not measured in the present study), may also curtail macrophage nitric oxide synthesis (20) , thus diminishing its support of uterine proliferation.
General Conclusions
Estrogen elicits a myriad of responses from multiple pathways that culminate in the uterotrophic response. This study provides statistically rigorous gene expression data that support decades of molecular and physiological research into uterine function and its response to estrogens. Despite the comprehensiveness of this study, many important genes were not represented on the GeneChip, and therefore it was not possible to place all responses into mechanistic or biological context. Moreover, limited information regarding RNA stability, timing of translation, posttranslational modification, and protein-protein interactions, as well as the sparse amount of gene annotation information, further confounded the interpretation of the temporal pattern of groups of genes that may share a pathway relationship. Nevertheless, several gene expression changes have been placed into cellular response context, thus providing more predictive bioindicators of estrogen action in the uterus. Overall, the uterus provides an ideal model for systematic assessment of the effects of estrogens at multiple levels, while also being a key target of estrogen action that displays numerous physiological outcomes.
